FWP - Forward Pharma granted Australian patent linked to multiple sclerosis therapy

The Australian government has awarded Forward Pharma (FWP +4.2%) a key patent linked to multiple sclerosis (MS) therapy. According to the details published by IP Australia Thursday, the patent bearing the application number 2019268049 is titled “pharmaceutical composition containing dimethyl fumarate for administration at a low daily dose.” Forward Pharma (NASDAQ:FWP) is a Danish biotech focused on the formulation of dimethyl fumarate (DMF) for the treatment of inflammatory and neurological indications, including MS.  DMF is an immunomodulator with the potential to improve clinical outcomes in patients with MS and other immune-mediated disorders. DMF is a key component in Biogen’s (NASDAQ:BIIB) MS therapy TECFIDERA. In 2016 the European Patent Office (EPO) invalidated a patent linked to DMF use in TECFIDERA. The company has appealed the decision, and a hearing is expected to take place next month.

For further details see:

Forward Pharma granted Australian patent linked to multiple sclerosis therapy